Recombinant Mouse IFN-γ (carrier-free)

Product Details

Source

Mouse IFN-γ, amino acids His23-Cys155 (Accession # NM_008337) was expressed in E. coli.

Molecular Mass

The 134 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 15,652 Da. The DTT-reduced and non-reduced protein migrate at approximately 13 kD by SDS-PAGE.

Purity

Purity is >98%, as determined by Coomassie stained SDS-PAGE.

Formulation

0.22 µm filtered protein solution is in 20 mM HEPES, 150 mM NaCl, 5 mM TCEP, pH 7.2.

Endotoxin Level

Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.

Concentration

10 and 25 µg sizes are bottled at 100 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.

Activity

Recombinant mouse IFNγ induces cytotoxicity in L929 cells in a dose dependent manner. The ED₅₀ of this effect is 0.5 - 3.5 ng/mL

Application

Bioassay

Recommended Usage

Use when high specific biological activity is required.

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

(PubMed link indicates BioLegend citation)

1. Reynolds DS, et al. 1987. J. Immunol. 139:767. (BA)
2. Dey S, et al. 2010. Mol. Cell. Biol. 30:2181. PubMed
3. Sun T, et al. 2012. Proc. Natl. Acad. Sci. USA 109:E2117. PubMed

Product Citations

1. Xiao Y, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:21. PubMed
2. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
3. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
4. Castillo E, et al. 2021. J Neurochem. 159:1008. PubMed
5. Rouanne M, et al. 2022. J Clin Invest. 132: . PubMed
6. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
7. Karino K, et al. 2023. Arthritis Rheumatol. 75:411. PubMed
8. Jahanbazi Jahan-Abad A, et al. 2023. Glia. 71:633. PubMed
9. Chen H, et al. 2022. Nat Commun. 13:7375. PubMed
10. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
11. Wei Z, et al. 2022. Nature. 609:348. PubMed
12. Tsukumo SI, et al. 2022. Sci Adv. 8:eabq0008. PubMed
13. Jiang S, et al. 2022. Sci Adv. 8:eabn6027. PubMed
14. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
15. Strine MS, et al. 2022. Cell Rep. 41:111593. PubMed
16. Mohammadpour H, et al. 2023. Cell Rep. 42:112250. PubMed
17. Kaur N, et al. 2023. Heliyon. 9:e14952. PubMed
18. Greer R, et al. 2016. Nat Commun. 7:13329. PubMed
19. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
20. Li Y, et al. 2022. J Lipid Res. :100273. PubMed
21. Mia MM, et al. 2020. PLoS Biol. 18:e3000941. PubMed
22. Davis B, et al. 2017. J Virol. 10.1128/JVI.00889-17. PubMed
23. Yu Y, et al. 2020. FASEB J. 34:15417. PubMed
24. Toulmin SA, et al. 2021. Nat Commun. 12:3993. PubMed
25. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
26. Inoue M, et al. 2016. Nat Neurosci. 19:1599-1609. PubMed
27. Lin H, et al. 2019. Infect Immun. 87:e00055-19. PubMed
28. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
29. Bremser A, et al. 2015. PLoS One. 10: 0137393. PubMed
30. Ji DX, et al. 2021. Elife. 10: . PubMed
31. Rai P, et al. 2021. Nat Immunol. 22:312. PubMed
32. Pereira M, et al. 2022. Cell Rep. 40:111225. PubMed
33. Jakic B, et al. 2021. Cell Death Dis. 12:187. PubMed
34. Wongchana W, et al. 2015. J Immunol. 195: 5337 - 5346. PubMed
35. Miranda K, et al. 2019. Front Immunol. 10:1049. PubMed
36. Eissa IR, et al. 2021. Int J Cancer. 149:214. PubMed
37. Nguyen TT, et al. 2022. Sci Adv. 8:eabn8614. PubMed
38. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
39. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
40. Chu SY, et al. 2019. Nat Commun. 10:1524. PubMed
41. Shepardson K, et al. 2016. MBio. 7: e00506-16. PubMed
42. Kanemaru H, et al. 2021. iScience. 24:103067. PubMed
43. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
44. Mohammadi N, et al. 2022. Front Cell Infect Microbiol. 11:784101. PubMed
45. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
46. Prieto–Fernández E, et al. 2020. Front Immunol. 11:586977. PubMed
47. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
48. Schweickert PG, et al. 2021. J Thromb Haemost. 19:161. PubMed
49. Fonderflick L, et al. 2022. Cells. 11:. PubMed
50. Yu Y, et al. 2021. FASEB J. 35:e21554. PubMed
51. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
52. Zhou X, et al. 2022. Front Pharmacol. 13:818166. PubMed
53. Kanemaru H, et al. 2022. STAR Protoc. 3:101128. PubMed
54. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
55. Ortiz A, et al. 2019. Cancer Cell. 35:33:00. PubMed
56. Yang L, et al. 2019. Front Immunol. 10:2020. PubMed
57. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
58. Bilotta AJ, et al. 2020. Cell Mol Gastroenterol Hepatol. 1.16875. PubMed
59. Kalliara E, et al. 2022. Front Immunol. 13:947213. PubMed
60. Hogg SJ, et al. 2022. Clin Epigenetics. 14:96. PubMed
61. Mantsounga CS, et al. 2022. Cell Rep. 38:110309. PubMed
62. Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
63. AuYeung AWK, et al. 2021. Sci Rep. 11:15290. PubMed

Antigen Details

Structure

Cytokine; dimer

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Embryonic Stem Cells

Biology Area

Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience, Stem Cells

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2

Gene ID

15978 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Certificate of Analysis